AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Milestone Pharmaceuticals Inc. Common Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG009DR4MP6
0.65▼ 0.05 (-7.76%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.70
Day's Range
0.63 – 0.71
52-Week Range
0.63 – 3.06
Volume
1.5M
Avg Volume
1.1M
Share Statistics
Shares Outstanding
Employees
38
Exchange
XNAS
Listed
2019-05-09
Share count as of August 12, 2026

Milestone Pharmaceuticals Inc. Common Shares (MIST) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Milestone Pharmaceuticals Inc. Common Shares (MIST)
What is Milestone Pharmaceuticals Inc. Common Shares's Market Cap?
Milestone Pharmaceuticals Inc. Common Shares's Market Cap is $80.7M, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's Enterprise Value?
Milestone Pharmaceuticals Inc. Common Shares's Enterprise Value is -$30.7M, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's EV / EBITDA?
Milestone Pharmaceuticals Inc. Common Shares's EV / EBITDA is 0.4×, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's Net Income (TTM)?
Milestone Pharmaceuticals Inc. Common Shares's Net Income (TTM) is -$84.0M, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's EBITDA?
Milestone Pharmaceuticals Inc. Common Shares's EBITDA is -$78.2M, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's Diluted EPS (TTM)?
Milestone Pharmaceuticals Inc. Common Shares's Diluted EPS (TTM) is -0.67, based on as-reported figures from SEC (XBRL) filings.
What is Milestone Pharmaceuticals Inc. Common Shares's Net Debt?
Milestone Pharmaceuticals Inc. Common Shares's Net Debt is -$111.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MISTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Loss
Product revenue, net——
License and other revenue
Total revenues——
Operating Expenses
Cost of product sales——
Research and development, net of tax credits
Selling, general and administrative———
Total operating expenses——
% of revenue4685.0%10042.4%——
Loss from operations
% of revenue-4585.0%-9942.4%——
Interest income
Interest expense
Net loss and comprehensive loss
% of revenue-5118.8%-10952.1%——
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)